

Paper No. \_\_\_\_  
Filed: May 2, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN LABORATORIES LIMITED,  
Petitioner,

v.

AVENTIS PHARMA S.A.,  
Patent Owner.

---

Case IPR2016-00712  
Patent 8,927,592

---

**PETITIONER MYLAN LABORATORIES LIMITED'S  
UPDATED LIST OF EXHIBITS**

**UPDATED LIST OF EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
1001	U.S. Patent No. 8,927,592 to Gupta
1002	Declaration of Dr. Rahul Seth
1003	Curriculum Vitae of Dr. Rahul Seth
1004	File History of 8,927,592 to Gupta
1005	U.S. Provisional Patent Application No. 61/256,160
1006	U.S. Provisional Patent Application No. 61/293,903
1007	U.S. Provisional Patent Application No. 61/355,834
1008	Sanofi-Aventis; <i>XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)</i> . Archived Oct. 23, 2008. ( <a href="https://web.archive.org/web/20081023121613/http://clinicaltrials.gov/ct2/show/NCT00417079">https://web.archive.org/web/20081023121613/http://clinicaltrials.gov/ct2/show/NCT00417079</a> ) (last accessed: March 14, 2017)
1009	Winqvist <i>et al.</i> , CAN. J. UROL. 15 (2008)
1010	Pivot <i>et al.</i> , ANN. ONCOL. 19 (2008) 1547-1552
1011	U.S. Patent No. 7,241,907 to Didier <i>et al.</i>
1012	Mita <i>et al.</i> , CLIN. CANCER RES., 15 (2009)
1013	Tannock <i>et al.</i> , N. ENGL. J. MED., 351 (2004) 1502-1512
1014	3:15-cv-03392 Complaint (D.N.J.)
1015	Booth <i>et al.</i> , NAT. REV. DRUG DISCOV. 3 (2003) 609-610
1016	STEDMAN'S MEDICAL DICTIONARY, 27 <sup>th</sup> Edition, 2000
1017	J. S. Abrams <i>et al.</i> , CANCER SUPP. 74 (1994) 1164-1176

1018	Kelland <i>et al.</i> , CANCER CHEMOTHER. PHARMACOL. 30 (1992) 444-450
1019	Verweij, <i>et al.</i> , ANN. ONCOL. 5 (1994) 495-505
1020	Galletti, <i>et al.</i> , CHEM. MEDCHEM., 2 (2007) 920-942
1021	Attard, <i>et al.</i> , PATHOL. BIOL., 54 (2006) 72-84
1022	Beardsley, <i>et al.</i> , CURR. OPIN. SUPPORT PALLIAT. CARE, 2 (2008) 161-166
1023	El-Maraghi and Eisenhauer, J. CLIN. ONCOL. 26 (2008) 1346-1354
1024	The Taxotere <sup>®</sup> Label
1025	Liu, WATER INSOLUBLE DRUG FORMULATION, First Edition, (2000) 525-568
1026	Affidavit of C. Butler, The Internet Archive
1027	Rosenberg, <i>et al.</i> , CANCER, 110 (2007) 556-563
1028	Gayther, <i>et al.</i> , CANCER RES. 60 (2000) 4513-4518
1029	Ratain and Sargent, EUR. J. CANCER, 45 (2009) 257-280
1030	Moul, REV. UROL. 6 (2004) S10-S17
1031	Joint Statement on Claim Construction, 3:15-cv-03392 (D.N.J.)
1032	J. B. Brady, Urological Institute Johns Hopkins Medical Institutions, <i>New Drugs for Prostate Cancer: Chemotherapy Transformed</i> , 2003
1033	Hospers, <i>et al.</i> , CURR. PHARM. DES. 14 (2008) 3020-3032
1034	Zhu, <i>et al.</i> , CANCER EPIDEMIOL. BIOMARKERS PREV. 15 (2006) 3-5
1035	Markman Hearing Transcript (excerpted), 3:15-cv-03392 (D.N.J.)
1036 (served but not filed)	Liu, WATER INSOLUBLE DRUG FORMULATION, First Edition (2000), excerpt

1037 (served but not filed)	J. B. Brady, Urological Institute Johns Hopkins Medical Institutions, <i>New Drugs for Prostate Cancer: Chemotherapy Transformed</i> , 2003
1038 (served but not filed)	Declaration of Patrick M. Medley
1039	Amended claim construction memorandum and order, <i>Sanofi-Aventis v. Fresenius Kabi USA et al.</i> , Lead Coordinated Case No. 14-7869 (D.N.J.)
1040	[Expunged]
1041	Transcript of Deposition of Dr. Oliver Sartor
1042	Transcript of Deposition of Michael E. Tate (Confidential)
1043	Reply Declaration of Dr. Rahul Seth (Confidential)
1044	Declaration of Robert McSorley (Confidential)
1045	<i>2008 NCCN Antiemesis Guidelines</i> , Internet Archive ( <a href="https://web.archive.org/web/20081001233326/http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf">https://web.archive.org/web/20081001233326/http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf</a> ) (Oct. 1, 2008) (last accessed: March 14, 2017)
1046	Takenaka, <i>et al.</i> , INT. J. UROL., 15 (2008)
1047	Trudeau, <i>et al.</i> , J. CLIN. ONCOL., 14 (1996)
1048	Hudis, <i>et al.</i> , J. CLIN. ONCOL., 14 (1996)
1049	Doenicke, <i>et al.</i> , INFLAM. RES., 53 (2004)
1050	Cabrespine, <i>et al.</i> , UROLOGY, 67 (2006)
1051	Padhani, <i>et al.</i> , BR. J. RADIOL., 74 (2001)
1052	NCT00168701 ClinicalTrials.gov Listing ( <i>Biogen Exhibit 1022A</i> )
1053	Michael, <i>et al.</i> , PROSTATE CANCER PROSTATIC DIS., 12 (2009)
1054	<i>Briefing Document for EOP2 Meeting</i> (1996) (Confidential)

1055	Defendant's Answer to the Complaint, Separate Defenses and Counterclaims, C.A. No.: 3:15-cv-3392, District of New Jersey, filed July 16, 2015
1056	Mylan Form 2016 Form 10-K
1057	Hoechst Aktiengesellschaft German Company, Encyclopaedia Britannica, April 21, 2009 ( <a href="https://www.britannica.com/topic/Hoechst-Aktiengesellschaft">https://www.britannica.com/topic/Hoechst-Aktiengesellschaft</a> ) (last accessed: March 14, 2017)
1058	<i>Intentionally left blank</i>
1059	<i>Approved Drug Products with Therapeutic Equivalence Evaluations</i> (ORANGE BOOK), 31 <sup>st</sup> Edition, 2011
1060	The Docetaxel Label (updated March 2012)
1061	Brooks, <i>FDA Grants Expanded Indication for Enzalutamide (Xtandi)</i> MEDSCAPE, 2004 ( <a href="http://www.medscape.com/viewarticle/831548">http://www.medscape.com/viewarticle/831548</a> ) (last accessed: March 13, 2017)
1062	Mitoxantrone Drug Information ( <a href="http://chemocare.com/chemotherapy/drug-info/Mitoxantrone.aspx">http://chemocare.com/chemotherapy/drug-info/Mitoxantrone.aspx</a> ) (last accessed: March 14, 2017)
1063	Estramustine Drug Information ( <a href="http://chemocare.com/chemotherapy/drug-info/estramustine.aspx">http://chemocare.com/chemotherapy/drug-info/estramustine.aspx</a> ) (last accessed: March 14, 2017)
1064	<i>Ketoconazole in Advanced Prostate Cancer: Have Tolerability Concerns Been Overstated?</i> DRUG THER PERSPECT. 15 (2000) ( <a href="http://www.medscape.com/viewarticle/406391">http://www.medscape.com/viewarticle/406391</a> ) (last accessed: March 14, 2017)
1065	<i>Jevtana Market Share US Performance Post Launch</i> , Sanofi Oncology, SA_JEV_2152659 – 670 (Confidential)
1066	<i>Off-Label Drug Use</i> , American Cancer Society ( <a href="https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/off-label-drug-use.html">https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/off-label-drug-use.html</a> ) (last accessed: March 14, 2017)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.